...
首页> 外文期刊>Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society >A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation.
【24h】

A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation.

机译:肝移植后头两年移植前MELD评分与死亡率之间的相关性。

获取原文
获取原文并翻译 | 示例

摘要

The Model for End-Stage Liver Disease (MELD) score is now the criteria for allocation in liver transplantation for patients with chronic disease. Although the score has been effective in the prediction of mortality in patients awaiting liver transplantation, its abilities to predict posttransplantation outcome need study. The aim of this study is to compare outcome in the first 2 years after liver transplantation according to the pretransplantation MELD score. The study includes 669 consecutive patients who underwent primary liver transplantation between December 1993 and October 1999 in a single transplant center. Patients who died of malignancy were excluded from the series. Pretransplantation MELD score was calculated using the United Network for Organ Sharing formula. Patients were stratified according to MELD score less than 15, 15 to 24, and 25 and higher. Posttransplantation survival at 3, 6, 12, 18, and 24 months was significantly lower in the groups with a higher MELD score. The difference wassignificant for hepatitis C and noncholestatic liver diseases, but not cholestatic diseases. In patients with a MELD score between 15 and 24, survival was significantly greater with cholestatic diseases and lower in patients with hepatitis C. In our study, pretransplantation MELD score correlates with survival in the first 2 years after transplantation. There is a survival advantage for patients with cholestatic diseases compared with those with hepatitis C. These findings suggest the need to readjust MELD score-based allocation decisions to consider patient outcome.
机译:现在,终末期肝病模型(MELD)评分是慢性疾病患者肝移植中分配的标准。尽管该分数在预测等待肝移植的患者的死亡率方面是有效的,但其预测移植后结果的能力仍需要研究。本研究的目的是根据移植前的MELD评分比较肝移植后头2年的结果。这项研究包括669名连续患者,他们于1993年12月至1999年10月在一个移植中心接受了原发性肝移植。因恶性肿瘤死亡的患者被排除在该系列之外。使用器官共享联合网络公式计算移植前的MELD评分。根据MELD评分将患者分为小于15、15至24,以及25或更高。在具有较高MELD评分的组中,移植后3、6、12、18和24个月的存活率显着降低。对于丙型肝炎和非胆汁淤积性肝病而言,差异显着,而对于胆汁淤积性疾病则无统计学意义。在MELD评分介于15到24之间的患者中,胆汁淤积性疾病的存活率明显更高,而丙型肝炎患者则更低。在我们的研究中,移植前的MELD评分与移植后最初2年的存活率相关。与丙型肝炎相比,胆汁淤积性疾病患者具有生存优势。这些发现表明,需要重新调整基于MELD评分的分配决策以考虑患者的结局。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号